Alzai Health Corp. has successfully completed its initial public offering, raising aggregate gross proceeds of $4,050,000 through the sale of 10,125,000 units at a price of $0.40 per unit. The offering included the exercise of the agent's over-allotment option for an additional 125,000 units. The company's common shares have resumed trading on the TSX Venture Exchange under the symbol "ALZI" after being halted on June 8, 2026. This capital infusion will support research and development, sales and marketing, and general working capital for the health technology firm specializing in AI-driven Alzheimer's Disease risk screening.

Each unit issued in the offering consists of one common share and one-half of one common share purchase warrant. Each whole warrant entitles the holder to purchase one common share at an exercise price of $0.60 until June 9, 2028. The company may accelerate the expiry of the warrants if the volume-weighted average trading price of the common shares reaches $0.90 for 10 consecutive trading days, subject to approval from the TSX Venture Exchange. The offering was conducted pursuant to a long form prospectus dated April 21, 2026, filed with securities commissions in Alberta, British Columbia, and Ontario.

Haywood Securities Inc. acted as the exclusive agent for the offering on a best efforts basis. As compensation, the agent received a cash commission of $283,500, representing 7% of the proceeds, and 708,750 agent's warrants, equal to 7% of the total units issued. Additionally, a corporate finance fee of $45,000 was paid, partially in cash and partially through the issuance of common shares. The agent's warrants are exercisable into one common share at $0.40 for a period of 24 months following the date of issuance.

Following the closing of the offering, Alzai Health Corp. has 64,147,682 common shares issued and outstanding. Directors, officers, and certain shareholders hold an aggregate of 23,489,722 common shares, which remain subject to escrow restrictions. The company focuses on early identification of cognitive decline using pre-existing patient data from routine clinical records, addressing a significant unmet need as approximately 80% of Alzheimer's patients are diagnosed past the mild stages of the disease.

Offering Details